Online inquiry

IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12404MR)

This product GTTS-WQ12404MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E gene. The antibody can be applied in Crohn's disease (CD), Psoriasis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916
UniProt ID P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12404MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7265MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ13800MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-10933
GTTS-WQ2228MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aVWF81
GTTS-WQ7620MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEN1029
GTTS-WQ9797MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JS002
GTTS-WQ1180MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABP 501
GTTS-WQ8928MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ8645MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW